This is a preview of subscription content, log in via an institution to check access.
Notes
From the IBM MarketScan Commercial Claims and Encounters Database, and the Medicare Supplemental and Coordination of Benefits Database.
Reference
Lokhandwala T, et al. Retrospective Analysis of Disease Severity, Health Care Resource Utilization, and Costs Among Patients Initiating Belimumab for the Treatment of Systemic Lupus Erythematosus. . Clinical Therapeutics : 6 Jul 2021. Available from: URL: http://doi.org/10.1016/j.clinthera.2021.06.009
Rights and permissions
About this article
Cite this article
Belimumab may improve clinical outcomes but increase costs for SLE patients in the USA. PharmacoEcon Outcomes News 883, 3 (2021). https://doi.org/10.1007/s40274-021-7874-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7874-x